Adastra Labs is in the process of becoming a standard cannabis processor and analytical testing lab in Canada. The company has already obtained its analytical testing license from Health Canada and expects to receive its standard processing license in the near term. The company owns a 13,000-square-foot former food packaging facility in British Columbia. The facility has been designed with good manufacturing practices (GMP) compliance in mind and is expected to feature a co-located in-process testing lab. The lab is expected to provide a full-spectrum of third-party analytical testing for licensed producers.
Adastra Labs plans to offer white label and toll processing services to cultivators looking to outsource their cannabis extraction and processing needs. The company also provides third-party cannabis testing services, which is a regulation that all licensed producers must adhere to. To date, the company has signed a supply agreement for dried flower and trim with SugarBud Craft Growers Corp. (TSXV:SUGR).
Adastra Labs’ company highlights include the following:
- Adastra Labs aims to be a leading standard cannabis processor.
- The company’s B2B strategy bridges the gap between cannabis cultivators and extraction.
- Adastra Labs plans to be a one-stop-shop for cannabis concentrates.
- The company owns a 13,000-square-foot facility in Langley, British Columbia, that is being built to GMP standards.
- Supply agreement in place with SugarBud.
- A highly diverse team of scientists, consultants and leaders lead Adastra Labs with strong collective experience in quality control and regulatory compliance in the cannabis industry.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).
Canopy Growth to Participate in BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.
For more information regarding the Company or the offering, please contact firstname.lastname@example.org, or